FPA Medical Management - FPAMQ Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FPA Medical Management - FPAMQ

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary Leger who wrote (487)	5/11/1998 12:32:00 AM
From: Douglas V. Fant	Read Replies (2) of 1110

Gary, With 30% annual growth rate in earnings (let's cut that to 20% to be conservative however), if FPAM steered analysts to reduce earnings estimates to $0.75 this year, then it should still trade at or around $15/share.... And with the Humana and Aetna business just starting I would not be surprised to see FPAM's revenue growth rate go even higher than 30% annually for the next couple of years.... Unless FPAM shows up with some problem different than what Oxford or Medpartners already experienced, then the analysts can price in properly such issues- they have experience at it. That's why I am saying that all of the bad news is priced into this stock IMO.... Sincerely, Doug F.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next